- As cancer numbers grow, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving patient outcomes.
- Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells while activating the body’s own immune system to attack the tumor.
- The company’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors.
Cancer remains a significant global health challenge, with certain types exhibiting particularly high mortality rates. Glioblastoma multiforme (“GBM”), triple-negative breast cancer (“TNBC”), sarcoma and lung cancer are among the most aggressive and deadly forms, necessitating urgent advancements in research and treatment. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer.
According to studies, GBM is the most common and aggressive primary brain tumor in adults (https://nnw.fm/7t1W3). Despite treatment, the median survival time is approximately 12 to 15 months, with a five-year survival rate of less than 7%. TNBC accounts for about 10–15% of all breast cancers (https://nnw.fm/qwmUR) and is characterized by its lack of estrogen, progesterone, and HER2 receptors, making it unresponsive to some of the most effective therapies. It tends to grow and spread faster than other breast cancers, with fewer treatment options and a poorer prognosis.
Lung cancer is the second most common cancer in both men and women in the United States (https://nnw.fm/5SAOr). In 2024, an estimated 234,580 new cases will be diagnosed, and approximately 125,070 people will die from the disease. The five-year survival rate remains low, emphasizing the need for improved therapeutic strategies.
In the face of these challenges, Calidi Biotherapeutics is at the forefront of developing novel treatments aimed at improving outcomes for patients with these and other cancers. Their approach leverages cutting-edge science to enhance the body’s natural defenses against cancer.
Calidi’s platform centers on the use of antitumor virotherapies that selectively infect and kill cancer cells. To enhance the delivery and efficacy of these viruses, Calidi employs patented technologies (extracellular enveloped viruses in its systemic platform and stem cells in its intratumoral platforms) designed to protect the virotherapy from the immune system until it reaches the tumor site. This method not only facilitates direct tumor destruction but also stimulates an immune response against cancer cells throughout the body.
Calidi’s therapeutic pipeline targets multiple cancer indications, with a focus on hard-to-treat tumors. Its pipeline includes RTNova, SuperNova and NeuroNova.
RTNova is a systemic platform that can be administered intravenously to target lung cancer and metastatic cancers. The technology includes a vaccinia virus enveloped with a human cell membrane designed to protect the viral payload from the body’s immune system during administration and home in on cancer cells.
Aimed at treating solid tumors, SuperNova combines mesenchymal stem cells with antitumor vaccinia virus to target and destroy cancer cells. This approach holds potential for addressing cancers such as head & neck, TNBC and soft tissue sarcoma, where conventional treatments have limited efficacy.
NeuroNova is a product designed for patients with newly diagnosed and recurrent high-grade gliomas, including GBM. NeuroNova utilizes neural stem cells engineered to deliver antitumor viruses directly to the tumor site. The therapy is advancing into Phase 1b/2 clinical trials, reflecting promising results.
Calidi Biotherapeutics’ innovative therapies have the potential to revolutionize cancer treatment by enhancing efficacy, stimulating immune response and addressing unmet needs. For cancers such as GBM, head & neck, TNBC, sarcoma and lung cancer, where current treatments are often inadequate, Calidi’s approach offers promising new potential.
The pressing need for effective treatments for these aggressive cancers underscores the importance of innovative research and development in oncology. Calidi Biotherapeutics’ pioneering work in harnessing the power of antitumor viruses and its patented technologies designed to protect the viral payload from the body’s immune system during administration represents significant advancements in the fight against these deadly diseases. As Calidi’s therapies progress through clinical trials, there is hope for improved outcomes and survival rates for patients facing these challenging cancers.
For more information, visit www.CalidiBio.com.
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
